PA
ADCT icon

Perceptive Advisors’s ADC Therapeutics ADCT Stock Holding History

Perceptive Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,495,805
Closed -$2.92M – 96
2023
Q1 		$2.92M Buy
+1,495,805
New +$5.52M 0.09% 85

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors's ADCT Position: Q2 2023 in Review

Perceptive Advisors sold out of ADC Therapeutics (ADCT) in Q2 2023, closing a stake of 1,495,805 shares — an estimated $2.92M sold.

Perceptive Advisors first reported a position in ADCT in Q1 2023 and held it in 1 quarter. The position peaked at $2.92M in Q1 2023. 56 funds tracked by Wall St. Rank hold ADCT as of Q2 2023.

  • Perceptive Advisors reported no remaining ADC Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Perceptive Advisors sold 1,495,805 ADC Therapeutics shares in Q2 2023, an estimated $2.92M.
  • Perceptive Advisors first reported a position in ADC Therapeutics in Q1 2023 and held it in 1 quarter.
  • Perceptive Advisors's ADC Therapeutics position peaked at $2.92M in Q1 2023.
  • 56 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2023.

Based on Perceptive Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.